Cargando…
Quantitative tandem mass spectrometry in the clinical laboratory: Regulation and opportunity for validation of laboratory developed tests
Tandem mass spectrometry is an important analytical tool for clinical laboratories, but tests developed and validated in-house (laboratory developed tests, or LDTs) require special consideration. In late 2022, the forecast for United States (U.S.) federal regulation of LDTs changed unexpectedly when...
Autores principales: | Stone, Judith A., van der Gugten, J. Grace |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10017411/ https://www.ncbi.nlm.nih.gov/pubmed/36937811 http://dx.doi.org/10.1016/j.jmsacl.2023.03.001 |
Ejemplares similares
-
Liquid Chromatography–Tandem Mass Spectrometry in Newborn Screening Laboratories
por: Gelb, Michael H., et al.
Publicado: (2022) -
Inter-laboratory validation of liquid chromatography–tandem mass spectrometry multi-mycotoxin determination in animal feed – method transfer from the reference laboratory to regional laboratories
por: Jedziniak, Piotr, et al.
Publicado: (2023) -
Review of the Use of Liquid Chromatography-Tandem Mass Spectrometry in Clinical Laboratories: Part I-Development
por: Rappold, Brian A.
Publicado: (2022) -
Use of Liquid Chromatography-Tandem Mass Spectrometry for Clinical Testing in Korean Laboratories: a Questionnaire Survey
por: Chae, Hyojin, et al.
Publicado: (2019) -
Impact of VALID Act implementation on mass spectrometry-based clinical proteomic laboratory developed tests
por: Lin, Yanchun, et al.
Publicado: (2023)